Incendia Therapeutics appoints Wendye Robbins as CEO

13 November 2023

Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO).

Dr Robbins is a pharmaceutical executive with more than 20 years of experience pioneering drug discovery and leading the growth of companies at all stages of development.

She is a seasoned biopharmaceutical leader with more than two decades of industry experience. Dr Robbins has shepherded multiple small and large molecule therapeutics through development and has a track record of building nascent life sciences companies with investors. She has served as an independent director for RAPT Therapeutics since 2019. She has raised around $2 billion in capital across the many companies she has supported.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK